Replimune narrows fiscal Q2 net loss to $57.1 million as TUDRIQEV launches
Replimune reported a net loss of $57.1 million for the fiscal second quarter ended September 30, 2026, down from $83.1 million a year earlier, as operating expenses fell. The company said TUDRIQEV became commercially available in the U.S. in early October and ended the quarter with $307.8 million in cash and cash equivalents, though the increase depended partly on an August 2026 stock offering that also raised the share count.
Key points
- Net loss was $57.1 million, or $0.54 per share, versus $83.1 million, or $0.90 per share, in the same quarter a year earlier.
- Research and development expenses were $34.4 million versus $57.9 million; selling, general and administrative expenses were $21.9 million versus $26.4 million.
- Cash and cash equivalents were $307.8 million at September 30, 2026, up from $268.9 million at March 31, 2026, including about $141.0 million in net offering proceeds from August 2026.
- Weighted average common shares outstanding rose to 105,176,101 from 91,915,769 a year earlier.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.